From: Therapeutic potential of venom peptides: insights in the nanoparticle-mediated venom formulations
Toxins | Mode of action | References |
---|---|---|
α-neurotoxins | Inhibition of muscle acetylcholine receptors (nAChR) | [56] |
κ-neurotoxins | Inhibition of neuronal acetylcholine receptors | [57] |
Muscarinic toxins (MT7) | Potent and specific inhibition of muscarinic receptors through allosteric modulations (structure in Fig. 2 (10)) | [58] |
Fasciculins | Inhibition of acetylcholinesterase (AChE) through allosteric interactions | [59] |
Calciseptine | Specific modulation of L-type calcium channels. Muscle relaxant and inhibits cardiovascular contractions | [60] |
Cardiotoxins | Interaction with phospholipids, Induces concentration dependent insulin release and not dependent on presence and absence of glucose | |
Mambin | Inhibition of ADP induced platelet aggregation, Inhibition of binding of platelet fibrinogen receptor GP IIb-IIIa to immobilized fibrinogen | [63] |
Exactin | Selective inhibition of factor X (FX) activation by extrinsic tenase complex (ETC) and thus acts as an anticoagulant. It has selective preferential action on ETC-FX complex | [64] |
ß-cardiotoxins | Inhibition of ß-adrenoreceptors (Binding affinity toward ß-1 and ß-2 subtypes) | [65] |
MTα | Selective inhibition of α-2B-adrenoreceptors. Concentration-dependent decrease in intracellular calcium (ca2+) | [66] |
Mambaglins | Inhibition of nociception (abolish pain) by inhibition of acid-sensing ion channels (ASICs) particularly ASIC1a and ASIC2a in central neurons and ASIC1b in nociceptors | [67] |
Tx7335 | Activation of potassium channels through KcsA by allosteric interaction causing reduction in inactivation of the channels | [68] |
Calliotoxin | Activation of voltage-gated sodium channels (Nav) by shifting voltage-dependence Nav1.4 to more hyperpolarized potential, subsequently inhibiting inactivation and production of large increased currents | [69] |